Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series

Swetha Kambhampati(Johns Hopkins University), Charalambos Andreadis(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Bita Fakhri(University of California, San Francisco), Shagun Arora(University of California, San Francisco), Mimi Lo(University of California, San Francisco), Lissa Gray(University of California, San Francisco), Lawry Kaplan(University of California, San Francisco), Khoan Vu(University of California, San Francisco)
Clinical Lymphoma Myeloma & Leukemia
December 26, 2019
10.1016/j.clml.2019.12.014
Cited by 24

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487